Related Experiment Videos
Carbapenem treatment of meningitis
1Department of Medical Microbiology, South African Institute for Medical Research, Johannesburg.
Abstract:
The carbapenem class of antibacterial agents is highly effective in vitro against the bacterial pathogens causing meningitis. Both imipenem and meropenem penetrate into the cerebrospinal fluid of children with inflamed meninges in the acute phase of meningitis. The wider clinical use of imipenem/cilastatin for the treatment of meningitis has been limited by the high incidence of seizures (up to 33%) in patients not having seizures prior to drug therapy. However, imipenem/cilastatin has been successfully used for the treatment of pneumococcal meningitis following failure of treatment with third-generation cephalosporins. The bacteriological and clinical efficacy of meropenem appears similar to that of cefotaxime in the management of meningitis in children and there was no significant propensity of either meropenem or cefotaxime to cause seizures. Meropenem has also been usefully employed to treat multi-resistant Pseudomonas aeruginosa meningitis. These data suggest that meropenem should be further investigated for use in the treatment of meningitis.
Insights
Meropenem shows promise for treating bacterial meningitis in children, demonstrating efficacy similar to cefotaxime without increased seizure risk. Further investigation into meropenem for meningitis treatment is recommended.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Background:
- Carbapenem antibiotics are effective against meningitis-causing pathogens.
- Imipenem and meropenem cross the blood-brain barrier into cerebrospinal fluid.
- Seizure risk limits imipenem/cilastatin use in meningitis treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of meropenem for pediatric meningitis.
- To compare meropenem with cefotaxime in meningitis management.
- To assess meropenem's utility against multi-drug resistant bacterial meningitis.
Main Methods:
- Clinical data review of carbapenem use in meningitis.
- Comparative efficacy analysis of meropenem and cefotaxime.
- Assessment of seizure incidence with carbapenem therapy.
Main Results:
- Meropenem demonstrates comparable efficacy to cefotaxime in pediatric meningitis.
- Meropenem and cefotaxime show no significant increase in seizure propensity.
- Meropenem has been effective against multi-resistant Pseudomonas aeruginosa meningitis.
Conclusions:
- Meropenem is a viable option for pediatric meningitis treatment.
- Meropenem offers an alternative to imipenem/cilastatin due to a lower seizure risk.
- Further research into meropenem for meningitis is warranted.